An international observational study on transition of care from paediatric to adult services for patients with mucopolysaccharidosis II Authors: Karolina M. Stepien, Olulade Ayodele, Joseph Muenzer, Roberto Giugliani, Christina Jackson, Laura Meade, Maurizio Scarpa, Christina Lampe, Jennifer Audi, Siddharth Jain, Mireia del Toro Published: 2026 ABSTRACT BackgroundTreatment for mucopolysaccharidosis II (MPS II; Hunter syndrome) via enzyme replacement therapy with intravenous idursulfase (Elaprase) has been available for over 15 years. This treatment has led to survival of more patients into adulthood and a concomitant rise in the need for transition of care from paediatric to adult care teams; however, implementation of transition pathways is not standardized.MethodsThis cross-sectional, non-interventional, multi-country qualitative interview study recruited patients with MPS II (n = 13), caregivers of patients with MPS II (n = 23) and healthcare professionals (n = 24) across six countries (Canada, Colombia, Germany, Mexico, the UK and the USA) to investigate approaches to transition of care in MPS II. Data were collected via a sociodemographic questionnaire, a clinical characteristics form and semi-structured interviews.ResultsThe interviews identified four overarching themes: transition of care approaches and their drivers, components of a successful transition programme, challenges or barriers to transitioning to adult care and suggested improvements to transition of care. Transition pathways showed high variability within and between countries. Participants reported essential items for successful transition, including continuity of care, a key contact person and empowering patients as early as possible in the process. Proposed improvements for transition included additional educational/support resources, psychological support and implementation of protocols to guide a standardized approach.ConclusionsOur study highlights the need for the establishment of common standards for the transition of care from paediatric to adult services for patients with MPS II. Based on the interview responses, we have proposed additional considerations for patients with neuronopathic MPS II. The findings may inform the development of effective transition practices for MPS II and other rare diseases, to optimize the transition of care experience for patients, caregivers and healthcare professionals.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12913-026-14463-9. Background Transition of care is defined as the ‘purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from paediatric to adult-oriented healthcare systems’ [1]. Transition is distinct from transfer of care, which is the final shift from paediatric to adult services. When improvements in patient management lead to an increase in life expectancy, the care of more patients transitions from paediatric settings to adult settings. This has increasingly been the case for mucopolysaccharidosis II (MPS II; Hunter syndrome; OMIM 309,900): a rare, life-limiting, progressive, X-linked lysosomal storage disease that affects multiple organ systems [2]. Patients can have a non-neuronopathic form of the disease or a neuronopathic form involving central nervous system dysfunction and cognitive impairment; both forms show a wide spectrum of clinical severity [2–4]. Treatment for MPS II via enzyme replacement therapy (ERT) with intravenous idursulfase (Elaprase, Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA) has been available for over 15 years [5]. Treatment with intravenous idursulfase has led to improved survival, with data showing median survival among treated patients was 33 years compared with 21 years for untreated patients [2]. However, the progressive nature of MPS II makes it likely that patients will require ongoing treatment and possible surgical intervention [6], which may be needed to manage progressive and chronic symptoms such as cardiac disease, orthopaedic problems, gastrointestinal problems, otitis and respiratory tract dysfunction [5, 7, 8]. Consequently, there is an increasing need to address the complex needs of patients with MPS II, particularly for those who are severely affected by the disease. Successful transition is required to prepare patients and/or caregivers to take on greater responsibility for disease management and treatment adherence than they may have needed to before [9, 10], which may include renewal of prescriptions, arranging home delivery of medication and reporting of adverse events, where relevant. In general, effective transition should include the development of a written policy, direct involvement of the young person in the process (as they may have different needs to children and adults), education and preparation period programmes, a coordinated transfer process with a named coordinator, an interested and capable adult clinical service provider, good communication, involvement with patient organizations to promote self-advocacy, administrative support and primary healthcare and social care involvement [10, 11]. However, such efforts may be complicated by a shortage of specialized physicians, which was highlighted in a survey of healthcare professionals (HCPs) working with adult patients with inherited metabolic diseases [12]. A survey conducted in France indicated that the support required by patients with MPS and their caregivers was dependent on the level of the patient’s disability rather than the type of MPS [13]. Similarly, a case series documenting the transition of care for patients with MPS revealed various approaches to the transition that were based on the needs of the individual patient [9]. The insufficient research on perspectives regarding transition processes specific to MPS II has led to a lack of clear and consistent implementation of recommendations across geographies and clinical settings for patients, their caregivers and HCPs. Rare metabolic diseases have variable and complex characteristics that need to be considered when planning for transition of care, which may require the involvement of a coordinated, multidisciplinary team [11, 12]. The multisystemic nature of MPS II generally necessitates medical and surgical management by a range of specialists, such as cardiologists, neurologists, otorhinolaryngologists, pulmonologists and specialist nurses [14]. The progressive nature of the disease also brings increasing risk of age-related morbidity and mortality, with respiratory and cardiac failure being common causes of death in teenage and adult patients with neuronopathic disease [4, 15]. Therefore, any transition of care plan for MPS II should take into account how different strands of care can be transitioned in a coordinated way [10], ensuring that patients have a medical team in place at all times who are able to address any urgent care needs and facilitate long-term management of their condition. Given the complexities of MPS II, there is a clear need to improve understanding of the current approaches to transition of care and how they can be optimized for different patient groups. Although qualitative research has provided valuable insights into patient and family experiences of MPS and treatment with ERT [16–18], a significant knowledge gap remains concerning the transition of care for patients with MPS II. In this multi-country qualitative interview study, we investigated the different perspectives on transition of care experiences among patients with MPS II, caregivers of patients with MPS II and HCPs treating patients with MPS II. The insights were intended to help inform best practice and improve care in adulthood for patients with MPS II, with potential applicability for those with other diseases with similar challenges. Methods Study design The objective of this study was to describe the transition from paediatric to adult care from the perspectives of patients with MPS II, caregivers of patients with MPS II and HCPs treating patients with MPS II. A cross-sectional qualitative descriptive study was conducted with these groups to explore models of transition of care from different countries including perceived gaps and unmet needs in the transition process. Participants completed a short sociodemographic questionnaire and underwent a 30-minute semi-structured interview. Patients and caregivers were also asked to complete a clinical characteristics form. Participants were recruited from Canada, Colombia, Germany, Mexico, the UK and the USA. The study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practice published by the International Society for Pharmacoepidemiology and the laws and regulations of the country in which the research was conducted. Ethical approval for the study was obtained from Salus Institutional Review Board in all countries except Canada. Ethical approval in Canada was obtained from Veritas. Participant eligibility and recruitment The study population comprised patients with MPS II aged ≥ 18 years and caregivers of patients with MPS II aged ≥ 13 years. Participants were required to be able to read and to understand the consent form, to complete an interview in their local language and to be aware of whether their care (or the care of the patient they cared for) had already transitioned from paediatric to adult services or whether they (or the patient they cared for) would or would not transition. Caregivers provided information from their own perspectives and therefore provided informed consent for themselves; the consent of the patient they cared for was not required. The study also included HCPs (physicians or nurses) with experience of treating patients in the past 7 years, including at least two patients with MPS II at the time of the study, and experience of treating at least one patient who survived into adolescence or adulthood in the past 5 years. Complete inclusion/exclusion criteria are provided in Additional File 1. Participants were recruited using ad hoc techniques by a specialized recruitment agency (Just Worldwide, London, UK). HCPs were recruited via emails or letters to key treatment centres, and patients/caregivers were recruited via targeted outreach to clinical centres, patient advocacy groups and on social media (methods varied depending on local regulations and cultural norms). All potential participants were screened into the study and only those who were uncontactable at the time of scheduling interviews were subsequently removed from the final study population. Recruitment efforts were made to ensure representation from all relevant participant groups across countries, including caregivers of patients with neuronopathic and non-neuronopathic MPS II, and representation of different physician and nurse specialties with experience of treating patients pre- and post-transition of care. Based on the observation that no new important concepts may emerge with additional interviews, data saturation was deemed to have been reached with the number of participants included, justifying the cessation of additional data collection and affirming an adequate sample size. All participants provided written informed consent. Assessments To collect information on MPS II disease status and details relating to participants’ engagement in transition of care services and processes, all participants were required to complete a short pre-interview sociodemographic questionnaire and patients and caregivers were also required to complete a clinical characteristics survey. Interviews, lasting for 30 minutes, were then performed via videoconference in the local language by trained and experienced interviewers, using a semi-structured interview guide (by the same PhD-qualified research psychologist in Canada, the UK and the USA [LM, one of the study authors], and by appropriately trained local researchers in Colombia, Germany and Mexico, working for Just Worldwide, London, UK). Further information regarding the backgrounds of the interviewers is provided in Additional File 1. Participants were asked open-ended questions to explore their experiences and perspectives relating to transition of care. This approach allowed responses to be collected in a more open and conversational manner than with prescriptive standardized patient-reported outcome tools. Given that all interview participants were over the age of 18 years and that all patient participants had non-neuronopathic disease, the interview approach was considered appropriate for all participants; specialized or child-centred interview techniques were not required. Interviewers used the same interview guide for both patient and caregiver participants and their responses were analysed together; further details on interview structure are provided in Additional File 1. Interviews took place between December 2022 and June 2023 and were audio-recorded and transcribed verbatim; if applicable, transcripts were translated into English. Data analysis Data obtained from the pre-interview questionnaire were analysed using descriptive statistics. Sample size was determined by the premise of thematic saturation, defined as the point at which no new relevant or important concepts emerged from the data and no additional relevant information would be gained through the conduct of additional interviews. Interview transcripts were imported and analysed using the MAXQDA qualitative analysis software (VERBI, Berlin, Germany). Identifiable information was removed before coding. Two coders trained in qualitative research methods conducted the data analysis, with the patient and caregiver samples analysed together, and the HCP sample analysed separately. The first three transcripts from each sample were coded by one coder, and the second coder performed an unblinded double code of the transcript. Once agreement was reached and discrepancies resolved, the remaining transcripts were analysed by one coder, using the agreed process. Regular meetings were held between the two coders to review and to discuss coding. Qualitative data from the open questions were analysed in line with thematic analysis, a qualitative approach to identify patterns of responses across all participants. Transcripts were inductively coded for themes pertaining to the current situation regarding transition of care from paediatric to adult services, including gaps and unmet needs. A description of the codes is provided in Additional File 1. The themes were used to identify trends and to provide a descriptive summary of similarities and differences within and between groups and countries. Results Participant characteristics A total of 62 participants were screened for the study; two participants were removed because they could not be contacted at the time of scheduling an interview. Overall, 60 participants (patients, n = 13; caregivers, n = 23; HCPs, n = 24) were recruited for this study. The patient sample comprised four patients (31%) from the USA, three patients (23%) from Germany, and two patients (15%) each from Colombia, Mexico and the UK; no patients were recruited from Canada. One participant from Colombia did not complete their pre-interview questionnaires. Demographic data are reported in Table 1. All patients who completed the pre-interview questionnaires were male, and the median (range) age of the patient population was 35 (26–67) years. Most patients were White (69%) and most (69%) received a diagnosis of MPS II at 2–10 years old. Owing to the requirement to be able to read and to understand the consent form, no patient participants with neuronopathic MPS II were included. All patients who completed the pre-interview questionnaires were receiving ERT at the time of recruitment. The most commonly reported clinical features were auditory impairment (92% of participants), vision impairment and cardiovascular issues (85% of participants for each). Table 1Patient participant sociodemographic and clinical characteristicsCharacteristic, n (%)Patients (N = 13)Age category, years 20–305 (38.5) 31–403 (23.1) >404 (30.8) Unreported1 (7.7)Sex Male12 (92.3) Unreported1 (7.7)Country USA4 (30.8) Germany3 (23.1) Colombia2 (15.4) Mexico2 (15.4) UK2 (15.4)Race/ethnicitya White or Caucasian9 (69.2) Latino or Hispanic2 (15.4) Middle Eastern1 (7.7) Unreported1 (7.7)Working status Full-time employment6 (46.2) Retired2 (15.4) Part-time employment1 (7.7) Student1 (7.7) Prefer not to answer1 (7.7) Other1 (7.7) Unreported1 (7.7)Level of education Master’s degree7 (53.8) Bachelor’s degree3 (23.1) Secondary/high school1 (7.7) Occupational certificate or diploma1 (7.7) Unreported1 (7.7)Marital status Single, never married7 (53.8) Married or domestic partnership3 (23.1) Co-habiting1 (7.7) Unreported2 (15.4)Age category at MPS II diagnosis, years 2–109 (69.2) >103 (23.1) Unreported1 (7.7)Currently receiving ERT Yes12 (92.3) Unreported1 (7.7)Intention to transition to adult services No intention to transition2 (15.4)b Transition planned1 (7.7)c Now fully in adult services9 (69.2) No response1 (7.7)Clinical featuresd Auditory impairment12 (100.0) Cardiovascular issues11 (91.7) Vision impairment11 (91.7) Respiratory issues9 (75.0) Musculoskeletal impairment8 (66.7) Fatigue5 (41.7) Seizures3 (25.0) Speech impairment1 (8.3)aRace/ethnicity was self-reported, according to predefined categoriesbBoth patients were from GermanycPatient was from GermanydOne patient did not complete the pre-interview questionnaire; data are reported for the remaining 12 participantsERT, enzyme replacement therapy; MPS II, mucopolysaccharidosis II Table 1Patient participant sociodemographic and clinical characteristicsCharacteristic, n (%)Patients (N = 13)Age category, years 20–305 (38.5) 31–403 (23.1) >404 (30.8) Unreported1 (7.7)Sex Male12 (92.3) Unreported1 (7.7)Country USA4 (30.8) Germany3 (23.1) Colombia2 (15.4) Mexico2 (15.4) UK2 (15.4)Race/ethnicitya White or Caucasian9 (69.2) Latino or Hispanic2 (15.4) Middle Eastern1 (7.7) Unreported1 (7.7)Working status Full-time employment6 (46.2) Retired2 (15.4) Part-time employment1 (7.7) Student1 (7.7) Prefer not to answer1 (7.7) Other1 (7.7) Unreported1 (7.7)Level of education Master’s degree7 (53.8) Bachelor’s degree3 (23.1) Secondary/high school1 (7.7) Occupational certificate or diploma1 (7.7) Unreported1 (7.7)Marital status Single, never married7 (53.8) Married or domestic partnership3 (23.1) Co-habiting1 (7.7) Unreported2 (15.4)Age category at MPS II diagnosis, years 2–109 (69.2) >103 (23.1) Unreported1 (7.7)Currently receiving ERT Yes12 (92.3) Unreported1 (7.7)Intention to transition to adult services No intention to transition2 (15.4)b Transition planned1 (7.7)c Now fully in adult services9 (69.2) No response1 (7.7)Clinical featuresd Auditory impairment12 (100.0) Cardiovascular issues11 (91.7) Vision impairment11 (91.7) Respiratory issues9 (75.0) Musculoskeletal impairment8 (66.7) Fatigue5 (41.7) Seizures3 (25.0) Speech impairment1 (8.3)aRace/ethnicity was self-reported, according to predefined categoriesbBoth patients were from GermanycPatient was from GermanydOne patient did not complete the pre-interview questionnaire; data are reported for the remaining 12 participantsERT, enzyme replacement therapy; MPS II, mucopolysaccharidosis II Patient participant sociodemographic and clinical characteristics aRace/ethnicity was self-reported, according to predefined categories bBoth patients were from Germany cPatient was from Germany dOne patient did not complete the pre-interview questionnaire; data are reported for the remaining 12 participants ERT, enzyme replacement therapy; MPS II, mucopolysaccharidosis II All 23 caregivers were parents of the patient for whom they were caring; seven (30%) were from the USA, four (17%) each were from Colombia, Mexico and the UK, and two (9%) each were from Canada and Germany. More than half of the caregivers were caring for patients aged > 18 years at the time of the survey (most of these patients received a diagnosis of MPS II in early childhood or infancy), and nine caregivers (39%) were caring for patients with neuronopathic MPS II (Table 2). Table 2Caregiver participant sociodemographic data and clinical characteristics of the patients with MPS II for whom care is providedCharacteristic, n (%)All caregivers (N = 23)Caregivers of patients with neuronopathicMPS II(n = 9)Caregivers of patients with non-neuronopathicMPS II(n = 9)Caregivers of patients with unknownMPS II type(n = 5)Age category, years 20–403 (13.0)1 (11.1)2 (22.2)0 41–508 (34.8)4 (44.4)2 (22.2)2 (40.0) 51–606 (26.1)4 (44.4)2 (22.2)0 >603 (13.0)003 (60.0) Unreported3 (13.0)03 (33.3)0Sex Female20 (87.0)8 (88.9)7 (77.8)5 (100.0) Male2 (8.7)1 (11.1)1 (11.1)0 Unreported1 (4.3)01 (11.1)0Country of residence USA7 (30.4)3 (33.3)1 (11.1)3 (60.0) Colombia4 (17.4)1 (11.1)3 (33.3)0 Mexico4 (17.4)4 (44.4)00 UK4 (17.4)02 (22.2)2 (40.0) Germany2 (8.7)02 (22.2)0 Canada2 (8.7)1 (11.1)1 (11.1)0Race/ethnicitya White or Caucasian13 (56.5)4 (44.4)4 (44.4)5 (100.0) Latino or Hispanic7 (30.4)5 (55.6)2 (22.2)0 White or Caucasian, Indigenous1 (4.3)01 (11.1)0 Mixed background1 (4.3)01 (11.1)0 Unreported1 (4.3)01 (11.1)0Working status Full-time employment9 (39.1)4 (44.4)5 (55.6)0 Full-time caregiver6 (26.1)4 (44.4)02 (40.0) Part-time employment4 (17.4)02 (22.2)2 (40.0) Prefer not to answer1 (4.3)001 (20.0) Unreported3 (13.0)1 (11.1)2 (22.2)0Level of education Secondary/high school7 (30.4)5 (55.6)1 (11.1)1 (20.0) Occupational certificate or diploma5 (21.7)1 (11.1)4 (44.4)0 Community college1 (4.3)001 (20.0) Bachelor’s degree7 (30.4)2 (22.2)2 (22.2)3 (60.0) Master’s degree1 (4.3)1 (11.1)00 Unreported2 (8.7)02 (22.2)0Marital status Married or domestic partnership14 (60.9)6 (66.7)4 (44.4)4 (80.0) Cohabiting3 (13.0)1 (11.1)2 (22.2)0 Separated2 (8.7)1 (11.1)1 (11.1)0 Widowed2 (8.7)1 (11.1)01 (20.0) Unreported2 (8.7)02 (22.2)0Age category of patient with MPS II, years 13–1810 (43.5)5 (55.6)4 (44.4)1 (20.0) >1812 (52.2)4 (44.4)4 (44.4)4 (80.0) Unreported1 (4.3)01 (11.1)0Sex of patient with MPS II Male20 (87.0)9 (100.0)7 (77.8)4 (80.0) Female2 (8.7)01 (11.1)1 (20.0) Unreported1 (4.3)01 (11.1)0Degree of cognitive impairment of patient with MPS II No impairment6 (26.1)05 (55.6)1 (20.0) Mild impairment4 (17.4)03 (33.3)1 (20.0) Moderate impairment7 (30.4)3 (33.3)1 (11.1)3 (60.0) Moderate–severe impairment1 (4.3)1 (11.1)00 Severe impairment5 (21.7)5 (55.6)00Working status of patient with MPS II Permanently unable to work due to illness8 (34.8)7 (77.8)01 (20.0) Student8 (34.8)1 (11.1)7 (77.8)0 Unemployed1 (4.3)001 (20.0) Full-time employment3 (13.0)003 (60.0) Other2 (8.7)1 (11.1)1 (11.1)0 Unreported1 (4.3)01 (11.1)0Level of education of patient with MPS II Primary/elementary school4 (17.4)3 (33.3)1 (11.1)0 Secondary/high school11 (47.8)3 (33.3)5 (55.6)3 (60.0) Occupational certificate or diploma2 (8.7)01 (11.1)1 (20.0) Bachelor’s degree1 (4.3)001 (20.0) Transition programme1 (4.3)01 (11.1)0 Other3 (13.0)3 (33.3)00 Unreported1 (4.3)01 (11.1)0Patient living with caregiver Yes22 (95.7)9 (100.0)8 (88.9)5 (100.0) Unreported1 (4.3)01 (11.1)0Age category of patient at MPS II diagnosis, years <26 (26.1)2 (22.2)2 (22.2)2 (40.0) 2–1016 (69.6)7 (77.8)6 (66.7)3 (60.0) >101 (4.3)01 (11.1)0Patient with MPS II currently receiving ERT Yes20 (87.0)8 (88.9)7 (77.8)5 (100.0) No3 (13.0)1 (11.1)2 (22.2)0If yes, age category of patient at ERT initiation, yearsb <22 (10.0)01 (14.3)1 (20.0) 2–1014 (70.0)6 (75.0)6 (85.7)2 (40.0) >102 (10.0)002 (40.0) Unreported2 (10.0)2 (25.0)00Intention for patient to transition to adult care No intention to transition7 (30.4)c4 (44.4)1 (11.1)2 (40.0) Transition planned5 (21.7)d2 (22.2)3 (33.3)0 Transitioning at the time of the study3 (13.0)01 (11.1)2 (40.0) Now fully in adult services8 (34.8)1 (11.1)4 (44.4)3 (60.0) No response1 (4.3)01 (11.1)0Clinical features of patient with MPS IIe Auditory impairment21 (91.3)7 (77.8)9 (100.0)5 (100.0) Cardiovascular issues20 (87.0)8 (88.9)7 (77.8)5 (100.0) Musculoskeletal impairment19 (82.6)7 (77.8)8 (88.9)4 (80.0) Respiratory issues15 (65.2)6 (66.7)5 (55.6)4 (80.0) Vision impairment16 (69.6)6 (66.7)7 (77.8)3 (60.0) Speech impairment13 (56.5)9 (100.0)3 (33.3)1 (20.0) Fatigue9 (39.1)5 (55.6)1 (11.1)3 (60.0) Seizures5 (21.7)5 (55.6)00aRace/ethnicity was self-reported, according to predefined categoriesbPercentages calculated using number of patients receiving ERT as the denominatorcCaregivers were from Mexico or the USAdCaregivers were from Canada or ColombiaePercentages add to over 100 because patients may experience more than one clinical feature of MPS IIERT, enzyme replacement therapy; MPS II, mucopolysaccharidosis II Table 2Caregiver participant sociodemographic data and clinical characteristics of the patients with MPS II for whom care is providedCharacteristic, n (%)All caregivers (N = 23)Caregivers of patients with neuronopathicMPS II(n = 9)Caregivers of patients with non-neuronopathicMPS II(n = 9)Caregivers of patients with unknownMPS II type(n = 5)Age category, years 20–403 (13.0)1 (11.1)2 (22.2)0 41–508 (34.8)4 (44.4)2 (22.2)2 (40.0) 51–606 (26.1)4 (44.4)2 (22.2)0 >603 (13.0)003 (60.0) Unreported3 (13.0)03 (33.3)0Sex Female20 (87.0)8 (88.9)7 (77.8)5 (100.0) Male2 (8.7)1 (11.1)1 (11.1)0 Unreported1 (4.3)01 (11.1)0Country of residence USA7 (30.4)3 (33.3)1 (11.1)3 (60.0) Colombia4 (17.4)1 (11.1)3 (33.3)0 Mexico4 (17.4)4 (44.4)00 UK4 (17.4)02 (22.2)2 (40.0) Germany2 (8.7)02 (22.2)0 Canada2 (8.7)1 (11.1)1 (11.1)0Race/ethnicitya White or Caucasian13 (56.5)4 (44.4)4 (44.4)5 (100.0) Latino or Hispanic7 (30.4)5 (55.6)2 (22.2)0 White or Caucasian, Indigenous1 (4.3)01 (11.1)0 Mixed background1 (4.3)01 (11.1)0 Unreported1 (4.3)01 (11.1)0Working status Full-time employment9 (39.1)4 (44.4)5 (55.6)0 Full-time caregiver6 (26.1)4 (44.4)02 (40.0) Part-time employment4 (17.4)02 (22.2)2 (40.0) Prefer not to answer1 (4.3)001 (20.0) Unreported3 (13.0)1 (11.1)2 (22.2)0Level of education Secondary/high school7 (30.4)5 (55.6)1 (11.1)1 (20.0) Occupational certificate or diploma5 (21.7)1 (11.1)4 (44.4)0 Community college1 (4.3)001 (20.0) Bachelor’s degree7 (30.4)2 (22.2)2 (22.2)3 (60.0) Master’s degree1 (4.3)1 (11.1)00 Unreported2 (8.7)02 (22.2)0Marital status Married or domestic partnership14 (60.9)6 (66.7)4 (44.4)4 (80.0) Cohabiting3 (13.0)1 (11.1)2 (22.2)0 Separated2 (8.7)1 (11.1)1 (11.1)0 Widowed2 (8.7)1 (11.1)01 (20.0) Unreported2 (8.7)02 (22.2)0Age category of patient with MPS II, years 13–1810 (43.5)5 (55.6)4 (44.4)1 (20.0) >1812 (52.2)4 (44.4)4 (44.4)4 (80.0) Unreported1 (4.3)01 (11.1)0Sex of patient with MPS II Male20 (87.0)9 (100.0)7 (77.8)4 (80.0) Female2 (8.7)01 (11.1)1 (20.0) Unreported1 (4.3)01 (11.1)0Degree of cognitive impairment of patient with MPS II No impairment6 (26.1)05 (55.6)1 (20.0) Mild impairment4 (17.4)03 (33.3)1 (20.0) Moderate impairment7 (30.4)3 (33.3)1 (11.1)3 (60.0) Moderate–severe impairment1 (4.3)1 (11.1)00 Severe impairment5 (21.7)5 (55.6)00Working status of patient with MPS II Permanently unable to work due to illness8 (34.8)7 (77.8)01 (20.0) Student8 (34.8)1 (11.1)7 (77.8)0 Unemployed1 (4.3)001 (20.0) Full-time employment3 (13.0)003 (60.0) Other2 (8.7)1 (11.1)1 (11.1)0 Unreported1 (4.3)01 (11.1)0Level of education of patient with MPS II Primary/elementary school4 (17.4)3 (33.3)1 (11.1)0 Secondary/high school11 (47.8)3 (33.3)5 (55.6)3 (60.0) Occupational certificate or diploma2 (8.7)01 (11.1)1 (20.0) Bachelor’s degree1 (4.3)001 (20.0) Transition programme1 (4.3)01 (11.1)0 Other3 (13.0)3 (33.3)00 Unreported1 (4.3)01 (11.1)0Patient living with caregiver Yes22 (95.7)9 (100.0)8 (88.9)5 (100.0) Unreported1 (4.3)01 (11.1)0Age category of patient at MPS II diagnosis, years <26 (26.1)2 (22.2)2 (22.2)2 (40.0) 2–1016 (69.6)7 (77.8)6 (66.7)3 (60.0) >101 (4.3)01 (11.1)0Patient with MPS II currently receiving ERT Yes20 (87.0)8 (88.9)7 (77.8)5 (100.0) No3 (13.0)1 (11.1)2 (22.2)0If yes, age category of patient at ERT initiation, yearsb <22 (10.0)01 (14.3)1 (20.0) 2–1014 (70.0)6 (75.0)6 (85.7)2 (40.0) >102 (10.0)002 (40.0) Unreported2 (10.0)2 (25.0)00Intention for patient to transition to adult care No intention to transition7 (30.4)c4 (44.4)1 (11.1)2 (40.0) Transition planned5 (21.7)d2 (22.2)3 (33.3)0 Transitioning at the time of the study3 (13.0)01 (11.1)2 (40.0) Now fully in adult services8 (34.8)1 (11.1)4 (44.4)3 (60.0) No response1 (4.3)01 (11.1)0Clinical features of patient with MPS IIe Auditory impairment21 (91.3)7 (77.8)9 (100.0)5 (100.0) Cardiovascular issues20 (87.0)8 (88.9)7 (77.8)5 (100.0) Musculoskeletal impairment19 (82.6)7 (77.8)8 (88.9)4 (80.0) Respiratory issues15 (65.2)6 (66.7)5 (55.6)4 (80.0) Vision impairment16 (69.6)6 (66.7)7 (77.8)3 (60.0) Speech impairment13 (56.5)9 (100.0)3 (33.3)1 (20.0) Fatigue9 (39.1)5 (55.6)1 (11.1)3 (60.0) Seizures5 (21.7)5 (55.6)00aRace/ethnicity was self-reported, according to predefined categoriesbPercentages calculated using number of patients receiving ERT as the denominatorcCaregivers were from Mexico or the USAdCaregivers were from Canada or ColombiaePercentages add to over 100 because patients may experience more than one clinical feature of MPS IIERT, enzyme replacement therapy; MPS II, mucopolysaccharidosis II Caregiver participant sociodemographic data and clinical characteristics of the patients with MPS II for whom care is provided aRace/ethnicity was self-reported, according to predefined categories bPercentages calculated using number of patients receiving ERT as the denominator cCaregivers were from Mexico or the USA dCaregivers were from Canada or Colombia ePercentages add to over 100 because patients may experience more than one clinical feature of MPS II ERT, enzyme replacement therapy; MPS II, mucopolysaccharidosis II Of the 24 HCPs (physicians, n = 12; nurses, n = 12) included in the study (Table 3), seven (29%) were from the USA and five (21%) each were from Mexico and the UK; HCPs were also recruited from Canada, Colombia (each n = 2 [8%]), and Germany (n = 3 [13%]). Most HCPs had 5–20 years of experience working with patients with MPS II (67%) and the majority had a current caseload of at least five patients with MPS II (54%). A similar number of paediatricians, adult physicians, and mixed paediatric and adult physicians were included in the study (n = 9 [38%], n = 7 [29%], and n = 8 [33%], respectively). Table 3HCP sociodemographic characteristicsCharacteristic, n (%)HCPs (N = 24)Country of residence USA7 (29.2) Mexico5 (20.8) UK5 (20.8) Germany3 (12.5) Canada2 (8.3) Colombia2 (8.3)Profession Physician12 (50.0) Nurse12 (50.0)Type of provider Paediatric9 (37.5) Mixed8 (33.3) Adult7 (29.2)Time working with patients with MPS II, years <53 (12.5) 5–105 (20.8) 11–2011 (45.8) >205 (20.8)Number of current patients with MPS II 2–410 (41.7) 5–106 (25.0) >107 (29.2) Unreported1 (4.2)Number of patients with MPS II to date who have survived into adulthood <59 (37.5) 5–1011 (45.8) >104 (16.7)HCP, healthcare professional; MPS II, mucopolysaccharidosis II Table 3HCP sociodemographic characteristicsCharacteristic, n (%)HCPs (N = 24)Country of residence USA7 (29.2) Mexico5 (20.8) UK5 (20.8) Germany3 (12.5) Canada2 (8.3) Colombia2 (8.3)Profession Physician12 (50.0) Nurse12 (50.0)Type of provider Paediatric9 (37.5) Mixed8 (33.3) Adult7 (29.2)Time working with patients with MPS II, years <53 (12.5) 5–105 (20.8) 11–2011 (45.8) >205 (20.8)Number of current patients with MPS II 2–410 (41.7) 5–106 (25.0) >107 (29.2) Unreported1 (4.2)Number of patients with MPS II to date who have survived into adulthood <59 (37.5) 5–1011 (45.8) >104 (16.7)HCP, healthcare professional; MPS II, mucopolysaccharidosis II HCP sociodemographic characteristics HCP, healthcare professional; MPS II, mucopolysaccharidosis II Characteristics of transition of care In our survey, a total of 18 patients and patients of caregivers had completed transition of care to adult services, 90% of whom reported transition conversations beginning after the patient reached 14 years of age. Of these 18 participants, eight (44%), six (33%) and four (22%) reported transition duration of <1 year, 1–2 years and >2 years, respectively. In addition, transition of care was planned for one patient from Germany and four patients of caregivers from Canada and Colombia, all of whom expected that the transition process would start when the patient was older than 14 years. Two patients in Germany and seven caregivers from Mexico and the USA stated there would be no transition of care. HCP-reported age of transition initiation and its duration varied across countries: the earliest was in the UK (patient aged 12 years), whereas the latest was in the USA (patient aged 19–21 years). Participants indicated that conversations with patients and caregivers regarding transition of care began approximately when the patient was 15 years old. Duration of transition varied between 6 months and 6 years, according to HCPs. Different approaches to transition were reported by HCPs: of the 23 who described the type of approach, 15 (65%) stated that patients make a formal transition from paediatric to adult care, whereas eight (35%) did not report a formal pathway. All HCPs from Canada and the UK reported a formal transition pathway, whereas none of the HCPs from Germany did so. Among the 15 HCPs who said that their hospital/facility had a formal transition process, there was a mix of transition pathways: nine (60% [Canada, n = 2; Mexico, n = 3; UK, n = 3; USA, n = 1]) reported following established policies, two (13%; both from the USA) stated that they used their clinical judgement, three (20% [UK, n = 2; USA, n = 1]) used both established policies and their own judgement and one (7% [Mexico]) did not provide an answer. Summary of interview findings Participant responses revealed both intra- and inter-country variation in transition. Four overarching themes and various sub-themes were identified (Fig. 1). Supporting participant quotes are presented in Tables 4 and 5, and in Additional File 1. Fig. 1Themes and sub-themes of key transition of care components identified by patients/caregivers and HCPs. HCP, healthcare professional; MPS II, mucopolysaccharidosis IITable 4Quotations from caregivers caring for patients with neuronopathic MPS II and/or moderate or severe impairmentThemeParticipant informationQuotationTransition approaches and their driversAbrupt transition initiated by medical and logistical circumstancesCaregiver of patient with neuronopathic MPS II (severe impairment) from Mexico“The children would no longer be treated in paediatrics because after the age of 16 they no longer had to be in paediatrics, that any disease outside the enzyme would be treated in the adult area”No process for transition of careCaregiver of patient with neuronopathic MPS II (severe impairment) from Canada“[Name]’s cardiologist retired, so then the conversation was, are we referred to the adult system, or are we staying in the paediatric system? [Name]’s doctor suggested staying in the paediatric system as long as possible, at least with this situation. He [doctor], who became a friend of mine, he passed away a month ago. So, we have to find a new ENT. So, it’s not like there’s an end date or anything like that. Right now, it seems circumstance by circumstance”Staged approaches to transitionCaregiver of patient with unknown MPS II type (moderate impairment) from USA“His [the patient’s] geneticist. I had asked them when he was 16; we had an appointment and I asked him: ‘You know, we’re looking at turning 18 here, we probably ought to start looking at what does that mean for his care’. So, it’s just kind of been an ongoing discussion since then, every once in a while, as new things come up”Individual circumstances resulting in delayed, partial or no transitionCaregiver of patient with neuronopathic MPS II (severe impairment) from Mexico“That’s all she [the doctor] told us, that the child would continue to be seen in paediatrics”Components of a successful transition programmeStrong support networksCaregiver of patient with neuronopathic MPS II (severe impairment) from Canada“And a couple of other parents, there’s five of us now, started having meetings to try to just do research and advocacy to find a way for our sons to live together once they become adults”Continued access to specialized careCaregiver of patient with neuronopathic MPS II (severe impairment) from USA“So that’s why we kind of went back there as well, because I knew they would let him stay for those specifics. Only because with an MPS child at 20–21 I don’t think there’s that many doctors in our area that are familiar with it. I don’t want to have to teach them everything about [the patient] when we already had doctors that knew him and treated him for years”Challenges or barriers to transitioning to adult careImplications of being in adult care with severe cognitive impairmentCaregiver of patient with neuronopathic MPS II (severe impairment) from Canada“Here we need to sign, it’s called an RA7 representation agreement section seven, or something. That means we’re his guardians, because once he goes into the hospital after he’s 19 he has that in place. We need that in place, so we can sign on his behalf”Perceived fragmentation and loss of supportCaregiver of patient with neuronopathic MPS II (severe impairment) from Canada“The biggest messaging I’ve received from parents and doctors is that the adult system basically has no idea what they’re doing or what to do”Suggested improvements to transition of careTransition roadmaps, case studies, medical information and beyondCaregiver of patient with unknown MPS II type (moderate impairment) from USA“A roadmap that could say, okay, these are the specific things you need to think about, like with guardianship, particularly. You don’t have to get guardianship but here’s what it would look like if you don’t have guardianship versus what it would look like with it. So, you can make an informed decision about if that’s something you really need to do”Eligible caregiver participants cared for patients aged ≥ 13 years. ENT, ear, nose and throat; MPS II, mucopolysaccharidosis IITable 5Quotations from HCPsThemeParticipant country and typeQuoteTransition approaches and their driversFragmented approach influenced by insurance and health systemsPaediatric doctor from Mexico“We are in this difficult transition. Within [healthcare system], the adult hospitals have no protocol for dealing with this type of illness. So, when I discharge my patients, they go to a different system than mine … Each hospital has its own criteria and decides whether or not to treat the patient that arrives. We still do not have unified criteria for sending a patient with lysosomal disease to continue treatment in an adult department”Mixed adult and paediatric doctor from USA“We have had maybe one or two where the insurance issue is a bit of a challenge in that once they age off their parent’s insurance, getting them on an insurance plan. Unfortunately, my institution is not contracted with most of the [Affordable Care Act] plans and so that has been a bit of a challenge for a couple of patients”Components of a successful transition programmeContinuity of specialized care facilitated by HCPsAdult nurse from UK“It tends to be the transition lead. You have that transition lead or the transition champion, as we are calling them now. If you have that champion in the service, they are the ones that will push for quite a lot to be done and it then gets everyone else involved and they start getting a bit of interest … The moment you lose that, it then just becomes another task for people to do”Challenges or barriers to transitioning to adult careComplexity of MPS II and unfamiliarity in adult carePaediatric doctor from Canada“But then they don’t have well-established interdisciplinary teams that might look after or coordinate all of their other healthcare needs once they reach the adult world. So, it is a little bit more fragmented. Then, we’re kind of dependent on transitioning to either family physicians, or internal medicine experts who might be willing to take on those patients, but it’s kind of challenging to identify sometimes people that would look after them”Logistical challenges of changing clinicsPaediatric doctor from Canada“When it’s a wholly different building, even if it’s just across the street, it could sometimes be the other side of the moon because they have to learn everything new”Disparity between chronological and mental agePaediatric doctor from Canada“The capacity of someone to become an adult doesn’t happen on a single day, but our system just isn’t built with that kind of flexibility”Suggested improvements to transition of careHandover materials or meetings between paediatric and adult care teamsPaediatric doctor from Mexico“I would prefer to speak personally and in detail with the new physician who will be treating the patient. Talk to him about the type of patient, his attitude to the disease, his social environment, his needs etc.”HCP, healthcare professional; MPS II, mucopolysaccharidosis II Themes and sub-themes of key transition of care components identified by patients/caregivers and HCPs. HCP, healthcare professional; MPS II, mucopolysaccharidosis II Table 4Quotations from caregivers caring for patients with neuronopathic MPS II and/or moderate or severe impairmentThemeParticipant informationQuotationTransition approaches and their driversAbrupt transition initiated by medical and logistical circumstancesCaregiver of patient with neuronopathic MPS II (severe impairment) from Mexico“The children would no longer be treated in paediatrics because after the age of 16 they no longer had to be in paediatrics, that any disease outside the enzyme would be treated in the adult area”No process for transition of careCaregiver of patient with neuronopathic MPS II (severe impairment) from Canada“[Name]’s cardiologist retired, so then the conversation was, are we referred to the adult system, or are we staying in the paediatric system? [Name]’s doctor suggested staying in the paediatric system as long as possible, at least with this situation. He [doctor], who became a friend of mine, he passed away a month ago. So, we have to find a new ENT. So, it’s not like there’s an end date or anything like that. Right now, it seems circumstance by circumstance”Staged approaches to transitionCaregiver of patient with unknown MPS II type (moderate impairment) from USA“His [the patient’s] geneticist. I had asked them when he was 16; we had an appointment and I asked him: ‘You know, we’re looking at turning 18 here, we probably ought to start looking at what does that mean for his care’. So, it’s just kind of been an ongoing discussion since then, every once in a while, as new things come up”Individual circumstances resulting in delayed, partial or no transitionCaregiver of patient with neuronopathic MPS II (severe impairment) from Mexico“That’s all she [the doctor] told us, that the child would continue to be seen in paediatrics”Components of a successful transition programmeStrong support networksCaregiver of patient with neuronopathic MPS II (severe impairment) from Canada“And a couple of other parents, there’s five of us now, started having meetings to try to just do research and advocacy to find a way for our sons to live together once they become adults”Continued access to specialized careCaregiver of patient with neuronopathic MPS II (severe impairment) from USA“So that’s why we kind of went back there as well, because I knew they would let him stay for those specifics. Only because with an MPS child at 20–21 I don’t think there’s that many doctors in our area that are familiar with it. I don’t want to have to teach them everything about [the patient] when we already had doctors that knew him and treated him for years”Challenges or barriers to transitioning to adult careImplications of being in adult care with severe cognitive impairmentCaregiver of patient with neuronopathic MPS II (severe impairment) from Canada“Here we need to sign, it’s called an RA7 representation agreement section seven, or something. That means we’re his guardians, because once he goes into the hospital after he’s 19 he has that in place. We need that in place, so we can sign on his behalf”Perceived fragmentation and loss of supportCaregiver of patient with neuronopathic MPS II (severe impairment) from Canada“The biggest messaging I’ve received from parents and doctors is that the adult system basically has no idea what they’re doing or what to do”Suggested improvements to transition of careTransition roadmaps, case studies, medical information and beyondCaregiver of patient with unknown MPS II type (moderate impairment) from USA“A roadmap that could say, okay, these are the specific things you need to think about, like with guardianship, particularly. You don’t have to get guardianship but here’s what it would look like if you don’t have guardianship versus what it would look like with it. So, you can make an informed decision about if that’s something you really need to do”Eligible caregiver participants cared for patients aged ≥ 13 years. ENT, ear, nose and throat; MPS II, mucopolysaccharidosis II Quotations from caregivers caring for patients with neuronopathic MPS II and/or moderate or severe impairment Eligible caregiver participants cared for patients aged ≥ 13 years. ENT, ear, nose and throat; MPS II, mucopolysaccharidosis II Table 5Quotations from HCPsThemeParticipant country and typeQuoteTransition approaches and their driversFragmented approach influenced by insurance and health systemsPaediatric doctor from Mexico“We are in this difficult transition. Within [healthcare system], the adult hospitals have no protocol for dealing with this type of illness. So, when I discharge my patients, they go to a different system than mine … Each hospital has its own criteria and decides whether or not to treat the patient that arrives. We still do not have unified criteria for sending a patient with lysosomal disease to continue treatment in an adult department”Mixed adult and paediatric doctor from USA“We have had maybe one or two where the insurance issue is a bit of a challenge in that once they age off their parent’s insurance, getting them on an insurance plan. Unfortunately, my institution is not contracted with most of the [Affordable Care Act] plans and so that has been a bit of a challenge for a couple of patients”Components of a successful transition programmeContinuity of specialized care facilitated by HCPsAdult nurse from UK“It tends to be the transition lead. You have that transition lead or the transition champion, as we are calling them now. If you have that champion in the service, they are the ones that will push for quite a lot to be done and it then gets everyone else involved and they start getting a bit of interest … The moment you lose that, it then just becomes another task for people to do”Challenges or barriers to transitioning to adult careComplexity of MPS II and unfamiliarity in adult carePaediatric doctor from Canada“But then they don’t have well-established interdisciplinary teams that might look after or coordinate all of their other healthcare needs once they reach the adult world. So, it is a little bit more fragmented. Then, we’re kind of dependent on transitioning to either family physicians, or internal medicine experts who might be willing to take on those patients, but it’s kind of challenging to identify sometimes people that would look after them”Logistical challenges of changing clinicsPaediatric doctor from Canada“When it’s a wholly different building, even if it’s just across the street, it could sometimes be the other side of the moon because they have to learn everything new”Disparity between chronological and mental agePaediatric doctor from Canada“The capacity of someone to become an adult doesn’t happen on a single day, but our system just isn’t built with that kind of flexibility”Suggested improvements to transition of careHandover materials or meetings between paediatric and adult care teamsPaediatric doctor from Mexico“I would prefer to speak personally and in detail with the new physician who will be treating the patient. Talk to him about the type of patient, his attitude to the disease, his social environment, his needs etc.”HCP, healthcare professional; MPS II, mucopolysaccharidosis II Quotations from HCPs HCP, healthcare professional; MPS II, mucopolysaccharidosis II Theme 1: Transition approaches and their drivers All patients and caregivers described a lack of information and clarity regarding the transition of care process. Except for Mexico and the UK, at least one participant from each country described an instance where they were preparing to transition to adult care, however there was no clear process to follow. Reaching adult age was the most common cause for abrupt transition; changes in proximity to paediatricians or emergency medical events were also reported as transition triggers. Transition was described as ‘staged’, ‘staggered’ or ‘carried out over time’ by participants from Canada, Colombia, the UK and the USA, allowing patients to prepare for the change. Patients and caregivers from all countries, except Canada, reported delayed, partial or no transition. Delays to transition were due to MPS II severity, the need for specialist treatment or hesitation from the paediatric team. For some patients, the paediatric teams delayed transition of care until they felt that the patient’s condition was stable enough; for others, care teams deemed the disease presentation so severe that they decided not to initiate transition of care. All HCP participants reported that the transition of care pathway for patients with severe health needs was often dictated by disease severity and life expectancy. Several non-US-based HCPs highlighted the lack of specific guidelines for transition in MPS II. The need for transition to be individualized was acknowledged, with some clinics forgoing transition altogether and keeping patients within the paediatric service. HCPs across all countries discussed flexibility in the transition process that enabled them to delay or stop transition, for example, in instances where the complexity of a patient’s condition warranted further medical investigation. Canadian HCPs noted that a transition process may not be initiated if patients were not likely to reach the planned age of transition. HCPs from Canada, Colombia, Mexico, the UK and the USA described various formal transition approaches, and all HCPs from Canada and the UK reported a formal approach. These approaches included conversations or the development of documents summarizing medical history to help the receiving team to learn about the incoming patient. Some HCPs from Canada, Mexico, the UK and the USA described dedicated meetings for the patient and their families to meet the adult care team. However, some HCPs from Canada, Colombia, Germany, Mexico and the USA reported fragmented processes due to insurance and local health system policies. Challenges with insurance systems also affected transition of care approaches and are described further in theme 3. Theme 2: Components of a successful transition programme Strong support networks were described by patients, caregivers and HCPs as being important for transition; these networks included other parents of patients with MPS II, psychological and spiritual support, MPS associations, friends and relatives. Support networks may also assist with finances and insurance issues. Strong relationships with care teams were reported as very important and were often built on years of interaction, with good relationships perceived as enhancing quality of care. Continuity of care was described as fundamental and customizable to the patient’s journey by participants from all countries; however, the meaning of ‘continuity’ differed between participants in patient and caregiver groups. For some, continuity referred to continued access to necessary treatments or specialized HCPs, whereas, for those who did not transition (with no plans to transition), continuity meant continuing care with their current providers. Key contact individuals were also regarded as very important to successful transition, and included social workers, the medical team, hospital managers and patient support programmes. HCPs aimed to achieve continuity by providing a bridge between the paediatric and adult teams, reassuring patients that they would be supported and taking steps to familiarize the patient with the incoming care team. Some clinics had a central contact point to coordinate support and care. Creating a feeling of empowerment and independence during the transition process was described as being important by patients and caregivers across all countries. Caregivers from the UK and the USA reported that the transition process helped to shape perceptions of their role when ownership of care moved to the patient, and also informed how they could support patient independence. Many HCPs perceived empowerment of patients/caregivers to be essential to a successful transition, with approaches to enhancing this including directing conversations to the patient (including on a one-to-one basis), speaking to them like an adult, helping them to feel confident in their decisions and acting as ‘cheerleaders’ as patients moved towards independence. HCPs from all countries stated that initiating transition conversations at an early age was beneficial. Early initiation gave HCPs the opportunity to tailor conversations to the needs of the family and to prepare them for the upcoming changes. The benefits of early transition were observed by both paediatric and adult providers: paediatric teams felt they were given the chance to start the process informally, whereas adult teams felt that patients and/or caregivers came to appointments better prepared for transition of care discussions. Theme 3: Challenges or barriers to transitioning to adult care Patients and caregivers highlighted changes in doctors or facilities, disjointed care across multiple facilities and delays as challenges of transition. Caregivers worried that these factors could be detrimental to patients’ health and well-being; one patient described them as disruptive to continuity in other aspects of their life. In addition, patients and caregivers reported a lack of guidance and clarity from care teams (e.g. with appointment structure); one caregiver described how poor communication led to transition feeling abrupt and fragmented. Some caregivers stated they felt that they had become solely responsible for managing the patient’s care. In some cases, patients with neuronopathic MPS II transitioned to adult care. Caregivers and HCPs described the challenges associated with this move for patients with lower cognitive function than expected for their chronological age. For example, caregivers reported an expectation in adult care that patients were independent and could attend appointments alone; however, this was considered problematic by caregivers who wished to advocate on behalf of the patient. Caregivers in Canada and the USA reported remaining legal guardians of patients so that they could continue to participate in care discussions. Conversely, some patients who remained in paediatric care beyond childhood despite having minimal cognitive impairment described their frustration with not being treated in an age-appropriate manner and being unable to access appropriate adult care. Caregivers from Colombia, Germany, Mexico and the USA described issues with insurance and healthcare providers, for example, challenges in determining the clinics that patients would be able to access after transition. Indeed, in the US system, it was apparent that some clinics would not accept certain insurance types. Challenges accessing treatment due to complications caused by insurance companies were also reported. For most patients in Colombia, Germany, Mexico and the USA, care access would change when the patient reached adult age owing to ‘ageing out’ of their parents’ insurance policy, which was an issue also recognized by HCPs. Logistical challenges of travelling were raised by patients and caregivers from all countries, including regular clinic visits, time spent travelling and the impact on work. Caregivers caring for patients with severe impairment also highlighted challenges associated with using public transport to travel to clinics. Challenges related to clinic location, or change in location, were particularly noted by HCPs from Mexico and Colombia, but also discussed by HCPs in Canada, the UK and the USA. The unfamiliarity of a new clinic location was consistently recognized as challenging by HCPs. Perception of loss of support due to fragmentation of adult services was the most recurring theme across patients and caregivers from all countries. Transition often resulted in fragmentation of care to multiple locations and care teams; however, patients and caregivers preferred to receive their care at a single location from a single, unified team. Participants reported long wait times, no check-ups, not knowing who to contact when in need of support/care, and a reduction in HCP sensitivity towards patients and families. HCPs acknowledged the loss of support services that was felt by patients and their caregivers. HCPs from Colombia, Germany, Mexico and the UK perceived that families felt less supported in adult care than in paediatric care because of reduced caregiver involvement. HCPs from Canada, the UK and the USA commented on other factors that may impact patient experience in adult care, such as longer wait times at appointments, shorter appointment durations and fewer nurses. The complexity and rarity of transitions prior to the availability of ERT in MPS II was reported to be associated with a lack of awareness and expertise among HCPs. Patients and caregivers from all countries emphasized that many physicians required better understanding of MPS II, particularly in adult settings, with participants reporting the need to advocate for their own care. Moreover, some doctors and clinics would not accept new patients with MPS II. Indeed, HCPs themselves regarded one of the greatest challenges of transition of care as the lack of familiarity with MPS II, its multiple support requirements and the lack of specialism in adult services. Many HCPs noted that the care pathway becomes fragmented after transition to adult care, impacting the ability of the patient to receive coordinated, complex care. HCPs recognized the concerns of families that felt that the transition would result in no longer being able to receive qualified and specialized care. Theme 4: Suggested improvements to transition of care Patients and caregivers stated that availability of more information about MPS II, the transition of care process, what adult care entails, how to contact adult care physicians, and case studies would be helpful in guiding them through transition. One patient from the UK suggested that advice from patients who had gone through transition of care would be useful. The need for standardized educational materials explaining transition, MPS II and treatment in accessible and easy-to-read formats was also reported by HCPs from Canada, Germany, Mexico and the UK. HCPs suggested a more multidisciplinary approach to handovers, involving the full care team, to improve communication between the paediatric physician and the adult physician, the hospital directors and administrative staff. This could be done remotely or through face-to-face meetings and supported by written materials. In addition, patients and caregivers from all countries, except Germany, felt that they required more psychosocial support, including support from social workers, emotional management support and peer networks; points of contact to guide people through transition or for when patients are unwell or struggling were also requested. In addition, patients and caregivers discussed the need for logistical support, including details of different specialist HCPs. In Canada, the UK and the USA, timing for initiating transition of care preferred by patients and caregivers was often earlier than what they experienced. Some participants stated that starting conversations about transition of care earlier would have allowed more time to identify and to establish the network of HCPs in adult care, and would prompt the paediatric team to improve connections with local specialized centres. Earlier conversations did not necessarily result in earlier initiation of transition of care, with some patients preferring to wait until they were older to begin the transition of care process, when they felt less burdened by other aspects of transition to adult life (e.g. education, starting a new job). HCPs from the UK and the USA suggested that a standardized transition of care process, with national guidelines to ensure all HCPs managing patients with MPS II provide a uniform service, would improve patient and caregiver experience. The need for improved psychosocial support was recognized by HCPs from all countries. HCPs suggested that additional support could be offered by psychologists and social workers, as well as peer support groups and networks. Discussion Our study in patients with MPS II, their caregivers and HCPs across six countries identified critical aspects of a successful transition of care programme for individuals with MPS II of varying severities, including patient/caregiver empowerment, effective support networks, strong relationships with new and existing care providers and robust continuity of care. We also identified several barriers to successful transition, such as the rarity of MPS II, disparity between chronological and mental age for patients with neurological forms of MPS II, change of clinic location, loss of established relationships, insurance issues and limited psychosocial support. To improve the transition of care process, participants suggested additional educational materials, increased psychosocial and logistical support, earlier conversations about transition and standardized guidelines/transition processes. Based on interview responses, we have also suggested additional considerations for transition processes for patients with neuronopathic forms of MPS II. The findings of our study are consistent with the ‘four Ps’ of transition (paper, process, people and place) advocated by McDonagh, 2007 [19]. For example, needs were identified for: greater educational materials (paper); improved communication about transition of care, initiating conversations and processes earlier, expectation management, and a structured approach (process); and key points of contact (people); as well as the importance of a convenient clinic location (place). In addition, our study highlighted specific issues that affect transition of care for patients with MPS II, such as the rare and complex nature of MPS II, including the variety of clinical features. MPS II, particularly severe and neuronopathic forms, present challenges that may require the involvement of multiple specialist adult care teams, rather than a single cohesive paediatric team. This may have led to the perception of fragmented care and to the logistical and insurance issues reported by patients and caregivers. Similarly, the rarity of MPS II means that many HCPs are inexperienced in managing the disease, which may have led to the perception by patients and caregivers of limited HCP expertise. For example, HCPs who are unfamiliar with the disease may be hesitant to perform some surgical procedures for patients with MPS II owing to complexities such as airway and breathing difficulties, valvular heart disease and the associated risks of anaesthesia in this population [4]. For patients with neuronopathic disease, these procedures may require significant preparation for the pre- and post-operative phases, and recovery may be challenging. For this reason, the transfer of care may be delayed until the surgery scheduled under the paediatric team’s care is completed and the patient has fully recovered. This may contribute to the variation in duration of transition that was reported by HCPs in our study. An important finding of our study is the need to maintain continuity of care throughout and beyond the transition process to reduce patient and caregiver experience of limited, fragmented and difficult-to-navigate adult services. This is supported by studies of transition for other diseases, including a qualitative systematic review that identified similar findings in rheumatology and a qualitative meta-synthesis of experiences from multiple chronic diseases [20, 21]. However, transition of care experience for MPS II is limited because, historically, few patients survived into adulthood. Perhaps unsurprisingly, therefore, many participants in this study perceived fragmented adult care systems and a lack of expertise in the adult care system. This may reflect that improvements to the MPS II treatment landscape have not yet provided sufficient clinical experience in adult care to lead to improved transition. This inexperience may be further compounded by the range of care teams required to support adults living with MPS II and its variable symptomology and clinical features. In particular, the increased survival of patients with neuronopathic MPS II into adulthood presents new challenges when considering the appropriateness of transition to adult care. This study has highlighted that, when care teams do proceed with transition for such patients, the adult care setting may sometimes present barriers for family members who feel the need to continue attending and advocating for their dependant with severe cognitive impairment. Although not specifically mentioned by the caregivers we interviewed, involving a palliative care team early in the transition process may help to support patients and caregivers as well as ensure better continuity of care. Previous metabolic disease transition of care surveys including HCPs from Europe [12] and the USA [22] have also identified barriers to effective transition that are consistent with those found in our study, such as healthcare fragmentation, a lack of a standardized approach, a lack of metabolic disease expertise, the complexity of metabolic diseases and the need for support for patients and caregivers undergoing transition, especially for patients who require ongoing specialized medical care and/or are cognitively impaired. Interestingly, these challenges were not reported in studies relating to transition in congenital heart disease, type 1 diabetes and rare bone diseases [23–25]. A review of transition of care processes for inherited metabolic diseases in the UK and USA identified other barriers that were not reported in our study, including differences in HCP specialty training backgrounds, challenges with physician recruitment and variation in the scope of care provided by clinics; stronger international collaboration on the transition of care process was suggested to strengthen its delivery [26]. Our study obtained insights from patients and caregivers and those from HCPs. Patients, caregivers and HCPs reported logistical issues as being important barriers to an effective transition. The unfamiliarity of a new clinic location, long travelling times and impact on work were raised as challenges by participants; these may have a greater impact on those with neuronopathic or severe forms of the disease. However, these issues were not discussed by HCPs in the previous HCP surveys on transition of care in metabolic diseases [12, 22]. Our study also identified discrepancies between HCP and patient/caregiver opinions. Formal transition processes were reported only by patients and caregivers in Mexico and the UK, whereas they were reported by HCPs from Canada, Colombia, Mexico, the UK and the USA. Patients and caregivers were focused on improving their understanding of the process, whereas HCPs commented on improving the overall approach to transition. HCPs reported timely conversations regarding transition; however, some patients and caregivers expressed a preference for these to be held earlier. HCPs also perceived family reservations about transition, but these were not reflected in interviews with patients or caregivers. By contrast, patients and caregivers noted communication issues and a need to advocate for their own/the patient’s care, especially if the patient was cognitively impaired and unable to make decisions on their own; however, these were not typically reported by HCPs. These differences highlight the requirement for an approach to transition that meets the needs of all parties. We had intended for our study to allow us to describe transition models, but they were highly variable, with frequent inconsistencies in implementation. Processes varied within and between countries, with standardized, flexible, individualized or fragmented approaches all reported. Current transition approaches were contingent on insurance and healthcare systems, national guidelines or specific clinic practices. Although a degree of transition variability is to be expected, there may be a need for standards of care to be developed to establish the overall principles of transition. Such standards should be created in the best interests of the individual and should address the differing needs of patients with neuronopathic and non-neuronopathic forms of MPS II. Based on our interview findings, we propose that considerations for patients with neuronopathic disease should include involving caregivers in care discussions and advocating for adult patients who may not be able to communicate their own needs, early coordination of multiple teams to manage complex and multifaceted patient needs, including psychological support and palliative care if necessary, and establishing transition processes in advance for cases that are complex. Transition to specialty clinics should happen simultaneously, to ensure a smoother transition process. This may involve advance visits to adult care centres so that patients and caregivers can become familiar with the adult care system. To further build upon and refine our suggestions, additional studies investigating the transition needs of patients with neuronopathic or severe forms of MPS II are needed. Limitations to this study include the relatively small sample size and recruitment challenges in some countries, both of which limit the generalizability of findings. However, steps were taken to ensure a diverse representation of transition experiences, and data saturation was achieved across participant samples. In addition, a broad range of participants was included in this study, including patients and caregivers of patients who had already completed transition. Since caregivers discussed their experiences of transition of care from the perspective of the patient they cared for, interviewers followed the same interview guide used for patient participants and responses from patients and caregivers were analysed together. Although this approach may have led to a duplication of related experiences, there was only one case where a caregiver who was interviewed provided care for a patient who was also interviewed in this study. Moreover, although this study captures insights from patients with a range of MPS II symptoms and severity, the study population does not reflect the collective view on the full spectrum of the disease, with insights related to neuronopathic MPS II limited to caregiver and HCP perspectives. Similarly, although individual insights were obtained on the impact of specific patient characteristics, such as disease severity, the relatively small sample size precluded a full analysis of the results according to these characteristics. General limitations inherent to a qualitative analysis are also applicable to this study; interview reporting is subjective and prone to recollection bias, and qualitative work lacks formal statistical analysis. This may lead to difficulties in establishing standardized approaches to transition of care that truly reflect the unmet needs of patients, caregivers and HCPs. Further research is warranted across other continents. Conclusions This study identified highly variable transition of care practices, both within and between countries, and also recognized several barriers to successful transition of care. Transition practices included formalized approaches with established pathways, fragmented approaches influenced by insurance and health systems, as well as individualized approaches owing to a lack of guidelines. Participants also reported abrupt, flexible or no transition based on health-, logistical- and insurance-related circumstances of the patient. Additional educational/support resources, psychosocial support and implementation of protocols to guide a standardized approach were identified as important to improving transition. Our findings can be used to help healthcare systems across the globe to develop transition of care processes that reflect the complexities and rarity of MPS II, highlighting important considerations for patients with neuronopathic MPS II, such as ensuring flexibility in transition approaches and including caregivers in care discussions when the patient transitions to adult services. Importantly, our study highlights challenges faced by patients and caregivers that need to be addressed during the transition process, such as communication/logistical issues and difficult-to-navigate systems, which may pose greater difficulties for patients with more severe disease. These insights can also be applied to transition of care processes for other diseases and may be particularly relevant and informative for rare genetic and metabolic diseases, diseases with neurological involvement or cognitive impairment, and patients with complex clinical needs, to ensure appropriate care in adulthood and to improve the transition experience for all parties involved. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1